Kardium Inc.

admin52025-09-30 09:59:30

About Kardium Inc.

Kardium Inc. was founded in 2007 and is headquartered in Vancouver, British Columbia, Canada. The company specializes in the research, development, and manufacturing of advanced medical devices for atrial fibrillation (AF) treatment. Kardium was recognized by LifeSciences BC as the Medical Technology Company of the Year in 2015 and 2021. In 2025, the company completed a $250 million financing round led by Janus Henderson Investors and Eckuity Capital.

Core Business and Product Pipeline

Kardium’s core business focuses on developing innovative systems for the treatment of atrial fibrillation. Its flagship product, the Globe® Pulsed Field System, is a breakthrough AF treatment solution that combines single-shot pulmonary vein isolation, high-definition mapping, and atrial ablation within a single catheter. The system features 122 electrodes and advanced software to record tissue contact, temperature, and electrical activity, enabling electrophysiologists to ablate and confirm success in real time. This unique integration offers superior efficiency and precision compared to conventional technologies.

Market Position and Competitive Advantages

Kardium holds a strong position in the atrial fibrillation treatment device market. The Globe® Pulsed Field System differentiates itself with integrated diagnostic and therapeutic capabilities. Results from the PULSAR trial, presented at the 2025 Heart Rhythm Society Annual Meeting, demonstrated a 78% one-year freedom rate from atrial arrhythmias in paroxysmal AF patients and a 0% rate of major device-related safety events. With over 500,000 catheter ablation procedures performed annually worldwide and a market valued at approximately $6 billion, Kardium’s Globe® system addresses significant unmet clinical needs.

Recent Developments

In 2025, Kardium secured $250 million in financing, led by Janus Henderson Investors and Eckuity Capital, with participation from T. Rowe Price Investment Management and Durable Capital Partners. This funding will support the commercialization of the Globe® system in Europe and clinical trials for FDA approval in the United States. Earlier, in 2021, Kardium raised $115 million in a round led by Fidelity Management & Research Company to expand its product development and clinical research activities.